UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

Seminars in oncology, 2015-08, Vol.42 (4), p.539-548

2015

Volltextzugriff (PDF)

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

PloS one, 2014-02, Vol.9 (2), p.e87705-e87705

2014

Volltextzugriff (PDF)

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

Journal for immunotherapy of cancer, 2015-09, Vol.3 (1), p.39-39, Article 39

2015

Volltextzugriff (PDF)

Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients

PloS one, 2016-01, Vol.11 (1), p.e0147153

2016

Volltextzugriff (PDF)

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

PloS one, 2021-01, Vol.16 (1), p.e0245287-e0245287

2021

Volltextzugriff (PDF)

CTLA-4 blockade and interferon-[alpha] induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

PloS one, 2021-01, Vol.16 (1), p.e0245287

2021

Volltextzugriff (PDF)

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients

PloS one, 2015-07, Vol.10 (7), p.e0132745-e0132745

2015

Volltextzugriff (PDF)

Anomaly mediated SUSY breaking scenarios in the light of cosmology and in the dark (matter)

The journal of high energy physics, 2011-05, Vol.2011 (5), Article 78

2011

Volltextzugriff (PDF)

Anomaly mediated supersymmetric models and Higgs data from the LHC

Physical review. D, 2013-06, Vol.87 (11), Article 115020

2013

Volltextzugriff (PDF)

Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy

American Society of Clinical Oncology educational book, 2017, Vol.37 (37), p.651-660

2017

Volltextzugriff (PDF)

Neoadjuvant therapy for melanoma: a promising therapeutic approach and an ideal platform in drug development

American Society of Clinical Oncology educational book, 2015 (35), p.e535-e542

Tarhini, Ahmad A

2015

Volltextzugriff (PDF)

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma

Melanoma research, 2017-08, Vol.27 (4), p.342-350

2017

Volltextzugriff (PDF)

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

Journal for immunotherapy of cancer, 2018-10, Vol.6 (1), p.112-112, Article 112

2018

Volltextzugriff (PDF)

Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy

American Society of Clinical Oncology educational book, 2017-05, Vol.37 (37), p.651-660

2017

Volltextzugriff (PDF)

219 Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A130-A131

2020

Volltextzugriff (PDF)

Correction to: Reply to Letter to the Editor “One-Anastomosis Gastric Bypass Revision for Gastroesophageal Reflux Disease: Long Versus Short Biliopancreatic Limb Roux-en-Y Gastric Bypass”

Obesity surgery, 2022-08, Vol.32 (8), p.2806-2806

2022

Volltextzugriff (PDF)

Erratum to Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach

Clinics in dermatology, 2013-07, Vol.31 (4), p.501-501

2013

Volltextzugriff (PDF)

726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A821-A821

2023

Volltextzugriff (PDF)

782-I Phase I dose escalation of SAR445710, a PDL1-IL15 targeted cytokine in metastatic and/or advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 2), p.A1819-A1819

2023

Volltextzugriff (PDF)

45 An integrative immune signature of complementary circulating and tumoral biomarkers maximizes the predictive power of adjuvant immunotherapeutic benefits for high-risk melanoma

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A52-A52

2023

Volltextzugriff (PDF)

666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A756-A756

2023

Volltextzugriff (PDF)

ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)

Clinical cancer research, 2013-12, Vol.19 (23), p.6597-6604

2013

Volltextzugriff (PDF)

Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9014-9014

2017

Volltextzugriff (PDF)

185 Global and local copy number aberration signatures as prognostic and immunotherapeutic predictors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A209-A209

2023

Volltextzugriff (PDF)

625 Immune priming IFx-Hu2.0 promotes antibody responses necessary for anti-PD1 responses in PD-1 refractory melanoma patients

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A713-A713

2023

Volltextzugriff (PDF)

1 – 25 von 225

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(203)
Mit Volltextzugriff
(192)

Publikationsform

Sprache

Englisch
(225)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Melanoma
(37)
Immunotherapy
(28)
Humans
(17)
Science & Technology
(17)
Cancer
(13)
Physical Sciences
(11)
Biomarkers
(10)
Melanoma - Drug Therapy
(10)
Patients
(10)
Physics
(9)
Regular And Young Investigator Award Abstracts
(9)
Tumors
(9)
Interferon
(8)
Ipilimumab
(8)
Medical Prognosis
(8)
Cytokines
(7)
Drug Therapy
(7)
Metastasis
(7)
Female
(6)
Male
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

CTLA-4 blockade and interferon-[alpha] induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients

Anomaly mediated SUSY breaking scenarios in the light of cosmology and in the dark (matter)

Anomaly mediated supersymmetric models and Higgs data from the LHC

Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy

Neoadjuvant therapy for melanoma: a promising therapeutic approach and an ideal platform in drug development

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy

219 Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients

Correction to: Reply to Letter to the Editor “One-Anastomosis Gastric Bypass Revision for Gastroesophageal Reflux Disease: Long Versus Short Biliopancreatic Limb Roux-en-Y Gastric Bypass”

Erratum to Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach

726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study

782-I Phase I dose escalation of SAR445710, a PDL1-IL15 targeted cytokine in metastatic and/or advanced solid tumors

45 An integrative immune signature of complementary circulating and tumoral biomarkers maximizes the predictive power of adjuvant immunotherapeutic benefits for high-risk melanoma

666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients

ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)

Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037

185 Global and local copy number aberration signatures as prognostic and immunotherapeutic predictors

625 Immune priming IFx-Hu2.0 promotes antibody responses necessary for anti-PD1 responses in PD-1 refractory melanoma patients

Aktive Filter

Suchergebnisse filtern